Skip to content
Open access

Diagnostic delay in SCN8A-related developmental and epileptic encephalopathy: clinical impact of genetic testing in early-onset drug-resistant epilepsy

Oct 2026 · ANPAbstract_CBN26 · 0 citations

Abstract

Case Presentation: 17-year-old female with seizure onset at four weeks of life was evaluated for long-standing drug-resistant epilepsy. Initial seizures consisted of vertical head movements evolving to tonic–clonic extension of two limbs with ocular and cephalic deviation to the right, followed by tonic extension of all four limbs and secondary generalized tonic–clonic activity with urinary incontinence. During the preictal phase the patient frequently approached her parents and placed her hand over her chest without verbalization. Postictal confusion and behavioral slowing were consistently observed. The patient had global developmental delay and limited verbal communication, although no focal neurological deficits were identified. Family history was notable for epilepsy in multiple relatives. Despite years of treatment with several antiseizure medications including lamotrigine, topiramate, clobazam, phenobarbital, phenytoin, levetiracetam and carbamazepine, seizure control remained inadequate. Video electroencephalogram monitoring demonstrated focal epileptiform discharges involving bilateral anterior and mesial temporal regions with background slowing predominating in the left frontal region, suggesting left frontotemporal epileptogenic dysfunction. Extensive investigation for acquired etiologies was negative. Given the early onset and refractory course, a targeted next generation sequencing panel for epilepsy-associated genes was performed. Genetic testing identified a heterozygous pathogenic variant in SCN8A (p.Arg1872Gln), establishing the diagnosis of SCN8A-related developmental and epileptic encephalopathy. Discussion: Genetic epilepsies are increasingly recognized as important causes of early-onset drug-resistant epilepsy. However, many patients experience prolonged diagnostic trajectories before molecular diagnosis is established. Delayed recognition of genetic etiologies may contribute to therapeutic uncertainty and prolonged exposure to ineffective treatments. SCN8A encodes the neuronal sodium channel Nav1.6 and pathogenic variants have been associated with developmental and epileptic encephalopathy characterized by early seizure onset, developmental impairment and pharmacoresistance. Identification of the genetic etiology may influence therapeutic decisions, guide counseling and improve understanding of disease mechanisms. Final Comments: This case highlights the significant diagnostic delay that can occur in genetic epilepsies beginning in early infancy. Incorporating genetic testing earlier in the evaluation of drug-resistant epilepsy may shorten the diagnostic pathway, clarify etiology and support more individualized clinical management.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.